<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="116018">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01943968</url>
  </required_header>
  <id_info>
    <org_study_id>HYMC-075-13</org_study_id>
    <nct_id>NCT01943968</nct_id>
  </id_info>
  <brief_title>Lysyl Oxidase, Semaphorin 7a and Semaphorin 3a in Patients With Systemic Sclerosis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hillel Yaffe Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hillel Yaffe Medical Center</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of our study is to find a biomarker for fibrosis or vasculopathy in systemic
      sclerosis. We will evaluate a possible correlation between semaphorin 7a, semaphorin 3a and
      lysyl oxidase and  fibrosis (lung and skin) or vasculopathy in patients with systemic
      sclerosis. The results obtained may help us diagnose these complications of systemic
      sclerosis and hopefully even monitor patient treatment.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Fibrin Enzyme Levels in Blood</measure>
    <time_frame>Six months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients will undergo blood tests before study and after six months to determine  levels of lysyl oxidase, semaphorin 7a and 3a and thus determine severity of the disease (systemic sclerosis).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>Systemic sclerosis patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Systemic sclerosis patients will have blood tested for fibrotic enzyme levels</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood test</intervention_name>
    <arm_group_label>Systemic sclerosis patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Systemic Sclerosis Patients

          -  Written consent to participation in study

        Exclusion Criteria:

          -  Serious active medical condition

          -  Other autoimmune rheumatic disease

          -  Current or past allergic/inflammatory reaction

          -  Liver disease

          -  Pregnant or breastfeeding

          -  Illegal drug or alcohol abuse
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doron River, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bnai Zion Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karina Zilber, MD</last_name>
    <phone>972-54-7870716</phone>
    <email>karinazilber@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bnai Zion Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Karina Zilber, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 12, 2013</lastchanged_date>
  <firstreceived_date>September 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
